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I
nterleukin (IL)-21, a cytokine pro-
duced by activated conventional CD4+
T lymphocytes and Natural Killer T cells,
drives anti-tumor immunity in the skin
and kidney. However IL-21 is also pro-
inflammatory in many tissues and pro-
motes colitis-associated colon cancer.
Understanding the biology of IL-21 in
these different situations is needed to
ensure maximal therapeutic benefit.
Introduction
The functional relationship between
inflammation and cancer was first pro-
posed by Rudolf Virchow nearly 150 y
ago, when he noticed leucocytes in tumors
and the surrounding stroma. Many epide-
miologic and molecular studies since then
showed that tumors can develop at sites
of infection and/or chronic inflammation
(Table 1).
1 It is however also clear that
inflammation-driven cell proliferation
alone is not per se sufficient to cause
cancer. For example in patients with
psoriasis, the chronic inflammatory process
sustains hyperproliferation of keratinocytes
but does not increase the risk of skin
cancer.
2 By contrast, cells that proliferate
in an environment rich in growth factors,
activated stroma, DNA-damaging agents
and mutagenic insults have a much higher
probability of becoming neoplastic.
Finally, inflammatory cells in the tumor
microenvironment may exert protective
antitumor activity.
3 The specific nature of
the inflammatory response and the tissue
context may thus determine the beneficial
vs. the detrimental effects of inflammation
in carcinogenesis.
The tumor microenvironment contains
both innate immune cells (e.g., macro-
phages, neutrophils, mast cells, myeloid-
derived suppressor cells, dendritic cells,
natural killer cells) and adaptive immune
cells (T and B lymphocytes). Tumor-
associated macrophages (TAMs) and T
cells are the most frequent immune cells
within the tumor microenvironment.
TAMs generally have a phenotype
described as “M2” or “alternatively acti-
vated macrophages,” oriented toward
suppressing adaptive immunity and pro-
moting tissue repair and angiogenesis.
4
High numbers of M2 TAMs correlate
with poor prognosis in many cancers.
4
Tumor progression can also be sustained
by T helper (Th) type 2 cells and
regulatory T cells (Tregs).
3 In contrast,
dendritic cells and M1 macrophages
producing IL-12, cytotoxic CD8+ T cells
and interferon (IFN)-c-producing Th1
cells can mediate anti-tumor immunity,
and their presence is associated with
better survival in some cancers (i.e., colon
cancer, melanoma, multiple myeloma,
and pancreatic cancer).
3 However, the
anti-tumor activity of these specific cell
subsets cannot be considered as a given
since there is evidence that CD8+ T cells
and Th1 cells can also promote rather
than inhibit tumorigenesis in some cir-
cumstances.
3 The factors that render
specific T cell subsets anti-tumorigenic in
some cancers and pro-tumorigenic in
others remain unknown, even though
the profile of cytokines produced by
these cells, rather than the type of cell
infiltrate, seems to play a decisive role in
influencing the growth and activity of the
tumor cells.
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IL-21 is a member of a large family of
cytokines (IL-2, IL-4, IL-7, IL-9 and
IL-15) whose receptors share a common
receptor c chain (cc).
5 IL-21 is made by a
range of activated CD4+ Th cells, includ-
ing Th1 and Th17 cells, activated NKT
cells, and T follicular helper cells.
5 IL-21
drives B cell differentiation into plasma
cells, regulates immunoglobulin produc-
tion, controls the proliferation and/or
effector function of both CD4+ and
CD8
+ T cells, limits the differentiation
of Tregs and can stimulate epithelial cells
and fibroblasts to produce inflammatory
mediators.
5 Like other cytokines in this
family, IL-21 has potent anti-tumor effects
due to its ability to expand the pool of
cytotoxic CD8+ T cells, NK cells and
NKT cells.
5 Beneficial IL-21-mediated
anti-tumor responses have been observed
in several independent experimental
models, where mice inoculated with
transplantable syngeneic tumor lines
(e.g., colon carcinoma, fibrosarcoma, pan-
creatic carcinoma, renal cell carcinoma,
melanoma) were successfully treated with
IL-21 via cytokine-gene transfection,
plasmid delivery or injection of the
recombinant protein.
6 In view of its anti-
tumor activity documented in pre-clinical
studies, IL-21-based therapy has been
proposed in the management of malig-
nant neoplasias. In Phase I and Phase IIa
clinical trials, IL-21 was well tolerated and
showed anti-tumor activity in patients
with renal cell carcinoma and metastatic
melanoma.
6
However, before generally considering
IL-21 as an anti-tumor cytokine, it should
be taken into consideration that the
majority of preclinical studies investigat-
ing the role of IL-21 in tumor develop-
ment have been conducted on implanted
tumor models. It remains unclear whether
the anti-tumor activity of IL-21 can be
generalized to spontaneously arising
tumors, including those boosted by
chronic inflammatory processes.
Involvement of IL-21 in
Immunopathology and
Colitis-Associated Colon Cancer
IL-21 can trigger inflammatory pathways
and promote tissue damage in many
organs. A pathogenic role of IL-21 has
been described in psoriasis, rheumatoid
arthritis, Type I diabetes, systemic lupus
erythematosus, graft-vs. host disease, and
inflammatory bowel diseases (IBD),
5 and
IL-21 blockers are now ready to move to
the clinic. IBD is the general term for
Crohn’s disease and ulcerative colitis
(UC), the two major chronic inflammat-
ory disorders of the intestine. IBD, and
particularly UC, represents an excellent
model for understanding the contribution
of IL-21 in tumorigenesis, since it is very
well known that patients with UC have
enhanced risk of colon cancer.
1 We have
recently shown that IL-21 is produced in
excess not only in the mucosa of patients
with UC, but also in the neoplastic areas
of patients with UC-associated colon
cancer and sporadic colorectal cancer.
7
Using the mouse model of colitis-asso-
ciated colon cancer induced by admin-
istration of azoxymethane (AOM)
followed by repeated oral administration
of dextran sulfate sodium (DSS), we
showed that IL-21 is over-produced in
the colonic neoplastic areas and that mice
deficient in IL-21 had less colonic inflam-
mation and were largely protected against
the development of colitis-associated colon
cancer.
7 Wild-type mice given a neutral-
izing IL-21 antibody developed fewer
smaller tumors than mice treated with a
control antibody.
7 In line with these data,
another study by Jauch and colleagues,
documented the tumor-promoting effect
of IL-21 in a very similar model of colitis-
associated colon cancer.
8
Analysis of mechanisms by which IL-21
promotes malignant cell growth in the
colon revealed that IL-21 sustains CD4+ T
cell infiltration in the tumor and peri-
tumor areas and enhances the production
of IL-6 and IL-17A (Fig. 1).
7 This is
particularly interesting since these two
cytokines are known to be involved in
tumor-associated inflammation and tumo-
rigenesis in the colon.
9 Mice deficient in IL-
21 show a marked downregulation of the
transcription factor STAT3, both in the
lamina propria and gut epithelium, and
reduced expression of Bcl-XL,aS T A T 3 -
induced anti-apoptotic protein.
7 This find-
ing is consistent with the demonstration
Table1. Cancer types associated with infection or chronic inflammation
Inflammatory condition Related cancer type
Barrett’s esophagus Esophageal adenocarcinoma
Lung inflammation (e.g., caused by smoking, asbestos, infection) Lung cancer
HBV- and HCV-induced chronic hepatitis Hepatocellular carcinoma
Primary sclerosing cholangitis Cholangiocarcinoma
Chronic cholecystitis Gallbladder cancer
H. pylori-induced gastritis Gastric cancer
Chronic pancreatitis Pancreatic carcinoma
Inflammatory bowel disease (i.e., ulcerative colitis and Crohn’s disease) Colorectal cancer
Endometriosis Endometrial carcinoma
Chronic pelvic inflammation Ovarian cancer
Schistosomiasis Bladder cancer
Chronic prostatitis Prostate cancer
Virus-induced lymphohistiocytosis T cell lymphoma
352 OncoImmunology Volume 1 Issue 3that human colon cancers overexpress active
STAT3, and that STAT3 activation in
tumor cells and tumor-associated inflam-
matory cells sustains tumor progression by
augmenting tumor survival, angiogenesis
and suppressing anti-tumor immunity . It
remains to be determined whether, follow-
ing AOM+DSS treatment, STAT3 is
directly activated by IL-21 or is dependent
on enhanced production of IL-6 and IL-
17A, given that these two cytokines activate
directly STAT3 in tumor cells.
9 This later
hypothesis seems to be more plausible
because mouse colonic epithelial cells do
not express the IL-21 receptor and corre-
spondingly fail to activate STAT3 when
stimulated with IL-21.
7
IL-21 suppresses the peripheral differ-
entiation of Foxp3
+ regulatory T cells,
5 so
it was expected that the milder colitis and
reduced CD4
+ T cell infiltrate seen in IL-
21-deficient mice might be associated with
higher percentage of Foxp3-expressing T
cells. These findings may however appear
surprising, because as pointed out above
Tregs inhibit anti-tumor immunity and
hence promote tumorigenesis. In this
context, it is however noteworthy that
the presence of Tregs has been associated
with anti-tumorigenic responses in gastro-
intestinal cancers.
10
Conclusion
It is now evident that cytokines have
powerful effects on tumor development, as
they generate an attractive environment
for the growth and spread of malignant
cells. Among these cytokines, particular
attention has recently been paid to IL-21,
since it seems to play a decisive role in
controlling tumorigenesis. Data emerging
from pre-clinical and clinical studies
indicates that forced overexpression of
IL-21 in tumor cells suppresses their
growth, through enhanced antitumor
immunity. Nonetheless, studies in models
of colitis-associated colon cancer strongly
support the tumor-promoting role of IL-
21, raising the possibility that IL-21 could
have opposing functions on the growth of
tumors, depending on the tissue context
and the local immune activation. Future
work is needed to confirm these observa-
tions as well as to determine whether IL-
21 is also involved in the development of
other cancers complicating the natural
history of patients with chronic inflam-
matory processes (e.g., Helicobacter pylori-
induced gastritis). If this is the case, the
use of IL-21 blockers could represent an
attractive and novel approach for pre-
venting and/or treating inflammation-
associated malignancies as well as the
underlying inflammation.
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Figure1. Putative functions of IL-21 in promoting colitis-associated colon cancer. In normal intestine APC-driven T cell activation is counter-regulated by
Tregs. During inflammation, activated T cells produce increased level of IL-21 that damps Treg differentiation and, in parallel, promotes T cell expansion
and subsequent secretion of pro-tumorigenic cytokines (e.g., IL-6 and IL-17A). These cytokines target DNA mutation-sensitized epithelial cells promoting
their proliferation through STAT3 activation and fostering tumor development. Finally, tumor-infiltrating cells sustain and amplify this pro-tumoral milieu
by secreting IL-21, IL-6 and IL-17A.
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